

Elastic Integrative Analysis of Randomized Trial and Real-World Data for Treatment Heterogeneity Estimation

Shu Yang^{*}, Donglin Zeng[†] and Xiaofei Wang^{‡§}

Abstract

Parallel randomized trial (RT) and real-world (RW) data are becoming increasingly available for treatment evaluation. Given the complementary features of the RT and RW data, we propose a test-based elastic integrative analysis of the RT and RW data for accurate and robust estimation of the heterogeneity of treatment effect (HTE), which lies at the heart of precision medicine. When the RW data are not subject to bias, e.g., due to unmeasured confounding, our approach combines the RT and RW data for optimal estimation by exploiting semiparametric efficiency theory. Utilizing the design advantage of RTs, we construct a built-in test procedure to gauge the reliability of the RW data and decide whether or not to use RW data in an integrative analysis. We characterize the asymptotic distribution of the test-based elastic integrative estimator under local alternatives, which provides a better approximation of the finite-sample behaviors of the test and estimator when the idealistic assumption required for the RW data is weakly violated. We provide a data-adaptive procedure to select the threshold of the test statistic that promises the smallest mean square error of the proposed estimator of the HTE. Lastly, we construct an elastic confidence interval that has a good finite-sample coverage property. We apply the proposed method to characterize who can benefit from adjuvant chemotherapy in patients with stage IB non-small cell lung cancer.

Keywords and phrases: Counterfactual; Least favorable confidence interval; Non-regularity; Precision medicine; Pre-test estimator; Semiparametric efficiency.

^{*}Department of Statistics, North Carolina State University, North Carolina 27695, U.S.A. Email: syang24@ncsu.edu.

[†]Department of Biostatistics, University of North Carolina at Chapel Hill

[‡]Department of Biostatistics and Bioinformatics, Duke University

[§]This research is supported by the NSF grant DMS 1811245, NIA grant 1R01AG066883, and NIEHS 1R01ES031651.

1 Introduction

Because of patient heterogeneity in response to various aspects of treatment, the paradigm of biomedical and health policy research is shifting from the “one-size-fits-all” treatment approach to precision medicine (Hamburg and Collins, 2010). Toward that end, an important step is to understand how treatment effect varies across patient characteristics, known as heterogeneity of treatment effect (HTE) (Rothwell, 2005, Rothwell et al., 2005). Randomized trials (RTs) are the gold standard method for treatment effect evaluation, because randomization of treatment ensures that treatment groups are comparable, and biases are minimized to the extent possible. However, due to eligibility criteria for recruiting patients, the trial sample is often limited in patient diversity, which renders the trial under-powered to estimate the HTE. On the other hand, big real-world (RW) data are increasingly available for research purposes, such as electronic health records, claims databases, and disease registries, that have much broader demographic and diversity compared to RT cohorts. Recently, several national organizations (Norris et al., 2010) and regulatory agencies (Sherman et al., 2016) have advocated using RW data to have a faster and less costly drug discovery process. Indeed, big data provide unprecedented opportunities for new scientific discovery; however, they also present challenges such as confounding due to lack of randomization.

The motivating application is to evaluate adjuvant chemotherapy for resected non-small cell lung cancer (NSCLC) at early-stage disease. Adjuvant chemotherapy for resected NSCLC has been shown to be effective in late-stage II and IIIA disease on the basis of RTs (Le Chevalier, 2003). However, the benefit of adjuvant chemotherapy in stage IB NSCLC disease is unclear. Cancer and Leukemia Group B (CALGB) 9633 is the only RT designed specifically for stage IB NSCLC (Strauss et al., 2008); however, it comprises about 300 patients which was undersized to detect clinically meaningful improvements for adjuvant chemotherapy. “*Who can benefit from adjuvant chemotherapy with stage IB NSCLC?*” remains an important clinical question. An exploratory analysis of CALGB 9633 showed that patients with tumor size ≥ 4.0 cm may benefit from adjuvant chemotherapy (Strauss et al., 2008). This benefit was also found in an analysis of a dataset from the National Cancer Database (NCDB) (Speicher et al., 2015), while an analysis based on the Surveillance, Epidemiology, and End Results (SEER) database found adjuvant chemotherapy extended survivals as compared to observation in all tumor size groups (Morgensztern et al., 2016). Although such population-based disease registries provide rich information citing the real-world usage of adjuvant chemotherapy, the concern is the confounding bias associated with RW data. Our goal is to integrate the CALGB 9633 trial with data from the NCDB to improve the RT findings regarding the HTE of adjuvant chemotherapy with both age and tumor size.

Many authors have proposed methods for generalizing treatment effects from RTs to the target population, whose covariate distribution can be characterized by the RW data (Buchanan et al., 2018, Zhao et al., 2019). When both RT and RW data provide covariate, treatment and outcome information, there are two main approaches for integrative analysis: meta analysis (e.g., Verde and Ohmann, 2015) and pooled patient data analysis. The major drawback of meta analysis is that it uses only aggregated information and does not distinguish the roles of the RT and RW data, both having unique strengths and weaknesses. The second approach includes all patients, but pooling the data from two sources breaks the randomization of treatments and therefore relies on causal inference methods to adjust for confounding bias (e.g., Prentice et al., 2005). Importantly, we cannot rule out possible unmeasured confounding in the RW data. Moreover, most existing integrative methods focused on average treatment effects (ATEs) but not on HTEs, which lies at the heart of precision medicine.

To acknowledge the advantages from the RT and RW data, we propose an elastic algorithm of combining the RT and RW data for accurate and robust estimation of the HTE. When the desirable assumptions required for an integrative analysis of the RT and RW data are met, we use the semiparametric efficiency theory (Bickel et al., 1993, Robins, 1994) to derive the semiparametric efficient estimator of the HTE. The main identification assumptions underpinning our method are (i) the transportability of the HTE from the RT and RW data to the target population and (ii) no unmeasured confounding in the RW data. We further consider the case when the RW data may violate the desirable assumption (ii). Utilizing the design advantage of RTs, we derive a test statistic to gauge the reliability of the RW data and decide whether or not to use the RW data in an integrative analysis. Therefore, our test-based elastic integrative estimator uses the efficient combining strategy for estimation if the violation test is not significant and retains only the RT data if the violation test is significant.

The proposed estimator belongs to pre-test estimation by construction (Giles and Giles, 1993) and is non-regular. Exact inference for pre-test estimation is difficult because the estimator depends on the randomness of the test procedure. This issue cannot be solved by sample splitting that divides the sample into two parts for testing and estimation, separately (Toyoda and Wallace, 1979). This is because sample splitting cannot bypass the issue of the additional randomness due to pre-testing and therefore the impact of pre-testing still remains. Our test statistic and estimator are constructed based on the whole sample data. To take into account the impact of pre-testing, we decompose the test-based elastic integrative estimator into orthogonal components, one is affected by the pre-testing and the other is not. This step reveals the asymptotic distributions of the proposed estimator to be mixture

distributions involving a truncated normal component with ellipsoid truncation and a normal component. To demonstrate the non-regularity issue, we also consider local alternatives (Staiger and Stock, 1997, Cheng, 2008, Laber and Murphy, 2011). Importantly, the local alternative formulates the situation when the assumption required for the RW data is weakly violated. This strategy provides a better approximation of the finite-sample behavior of the proposed estimator. Under this framework, we provide a data-adaptive procedure to select the threshold of the test statistic that promises the smallest mean square error (MSE) of the proposed estimator. Lastly, we propose an elastic procedure to construct confidence intervals (CIs), which is adaptive to the local alternative and the fixed alternative and has good finite-sample coverage properties.

This article is organized as follows. Section 2 introduces the basic setup, the HTE, the identification assumptions, and semiparametric efficient estimation. Section 3 establishes a test statistic for gauging the reliability of the RW data, a test-based elastic integrative estimator, the asymptotic properties, and an elastic inference procedure. Section 4 presents a simulation study to evaluate the performance of the proposed estimator in terms of robustness and efficiency. Section 5 applies the proposed method to combined RT and RW data to characterize the HTE of adjuvant chemotherapy in patients with stage IB non-small cell lung cancer. We relegate technical details and all proofs to the supplementary material.

2 Basic setup

2.1 Notation, the HTE, and two data sources

Let $A \in \{0, 1\}$ be the binary treatment, Z a vector of pre-treatment covariates of interest with the first component being 1, X a vector of auxiliary variables including Z , and Y the outcome of interest. To fix ideas, we consider Y to be continuous or binary, although our framework can be extended to general-type outcomes including the survival outcome. We follow the potential outcomes framework (Neyman, 1923, Rubin, 1974) to define causal effects. Under the Stable Unit of Treatment Value assumption, let $Y(a)$ be the potential outcome had the subject been given treatment a , for $a = 0, 1$. By the causal consistency assumption, the observed outcome is $Y = Y(A) = AY(1) + (1 - A)Y(0)$.

Based on the potential outcomes, the individual treatment effect is $Y(1) - Y(0)$, and the HTE can be characterized through $\tau(Z) = \mathbb{E}\{Y(1) - Y(0) \mid Z\}$. For a binary outcome, $\tau(Z)$ is also called the causal risk difference. In clinical settings, the parametric family of HTEs is desirable and has wide applications in precision medicine for the discovery of optimal treatment regimes that are tailored to individual's characteristics (Chakraborty and Moodie,

2013). We assume the HTE function to be

$$\tau(Z) = \tau_{\psi_0}(Z) = \mathbb{E}\{Y(1) - Y(0) \mid Z; \psi_0\}, \quad (1)$$

where $\psi_0 \in \mathbb{R}^p$ is a vector of unknown parameters and p is fixed.

We illustrate the HTE function in the following examples.

Example 1. (Tian et al., 2014; Shi et al., 2016) For a continuous outcome, a linear HTE function is $\tau_{\psi_0}(Z) = Z^\top \psi_0$, where each component of ψ_0 quantifies the treatment effect of each Z .

Example 2. (Tian et al., 2014; Richardson et al., 2017) For a binary outcome, an HTE function for the causal risk difference is $\tau_{\psi_0}(Z) = \{\exp(Z^\top \psi_0) - 1\} / \{\exp(Z^\top \psi_0) + 1\}$, ranging from -1 to 1 .

To evaluate the effect of adjuvant chemotherapy, let Y be the indication of cancer recurrence within 1 year of surgery. Consider the HTE function in Example 2 with $Z = (1, \text{age}, \text{tumor size})^\top$ and $\psi_0 = (\psi_{0,0}, \psi_{0,1}, \psi_{0,2})^\top$. This model entails that, on average, the treatment would increase or decrease the risk of cancer recurrence had the patient received adjuvant chemotherapy by $|\tau_{\psi_0}(Z)|$, and the magnitude of increase depends on age and tumor size. If $Z^\top \psi_0 < 0$, it indicates that the treatment is beneficial for this patient. Moreover, if $\psi_{0,1} < 0$ and $\psi_{0,2} < 0$, then older patients with larger tumor sizes would have greater benefit from adjuvant chemotherapy.

We consider two independent data sources: one from the RT study and the other from the RW study. Let $\delta = 1$ denote RT participation, and let $\delta = 0$ denote RW study participation. Let V summarize the full record of observed variables (A, X, δ, Y) . The RT data consist of $\{V_i : \delta_i = 1, i \in \mathcal{A}\}$ with sample size m , and the RW data consist of $\{V_i : \delta_i = 0, i \in \mathcal{B}\}$ with sample size n , where \mathcal{A} and \mathcal{B} are sample index sets for the two data sources. Our setup requires the RT sample and the RW sample to contain the information on Z but may have different sets of auxiliary information in X . The total sample size is $N = m + n$. Generally, n is larger than m . In our asymptotic framework, we assume both m and n go to infinity, and $m/n \rightarrow \rho$, where $0 < \rho < 1$.

For simplicity of exposition, we use the following notation throughout the paper: \mathbb{P}_N denotes the empirical measure over the combined RT and RW data, $M^{\otimes 2} = MM^\top$ for a vector or matrix M , $\mathbb{E}_a(\cdot)$ and $\mathbb{V}_a(\cdot)$ are the asymptotic expectation and variance of a random variable, $A_n \perp\!\!\!\perp B_n$ denotes A_n is independent of B_n , $A_n \sim B_n$ denotes that A_n follows the same distribution as B_n , and $A_n \overset{\sim}{\sim} B_n$ denotes that A_n and B_n have the same asymptotic distribution as $n \rightarrow \infty$.

2.2 Identification of the HTE from the RT and RW data

The fundamental problem of causal inference is that $Y(0)$ and $Y(1)$ are not jointly observable. Therefore, the HTE is not identifiable without additional assumptions. Let $e_\delta(X) = \mathbb{P}(A = 1 \mid X, \delta)$ be the propensity score. We first consider an idealistic situation satisfying the following assumptions.

Assumption 1. $\mathbb{E}\{Y(1) - Y(0) \mid X, \delta\} = \tau(Z)$.

Assumption 2. $Y(a) \perp\!\!\!\perp A \mid (X, \delta = 1)$ for $a \in \{0, 1\}$, and $0 < e_1(X) < 1$ for all $(X, \delta = 1)$.

Assumption 3. $Y(a) \perp\!\!\!\perp A \mid (X, \delta = 0)$ for $a \in \{0, 1\}$, and $0 < e_0(X) < 1$ for all $(X, \delta = 0)$.

Assumption 1 states that the HTE function is transportable from the RT and RW sample to the target population. It holds if Z captures all important treatment effect modifiers. This assumption is a common assumption in the data integration literature. Stronger versions of Assumption 1 are also been considered in the literature, including the ignorability of study participation, i.e., $\{Y(0), Y(1)\} \perp\!\!\!\perp \delta \mid X$ (Stuart et al., 2011, Buchanan et al., 2018), or the mean exchangeability, i.e., $\mathbb{E}\{Y(a) \mid X, \delta\} = \mathbb{E}\{Y(a) \mid X\}$ for $a = 0, 1$ (Dahabreh et al., 2018).

Assumptions 2 and 3 entail that treatment assignment in the RT and the RW study follows some randomization mechanisms based on the pre-treatment variables X , and all subjects have positive probabilities of receiving each treatment. Assumption 2 holds by the design of complete randomization of treatment, where the treatment is independent of the potential outcomes and covariates, i.e., $Y(a) \perp\!\!\!\perp (A, X) \mid \delta = 1$. It also holds by the design of stratified block randomization of treatment based on discrete X , where the treatment is independent of the potential outcomes within each stratum of X . Moreover, the propensity score $e_1(X)$ is known by design. Assumption 3 holds if the observed covariates X capture all the confounding variables that are related to the treatment and outcome in observational studies. Moreover, the propensity score $e_0(X)$ is usually unknown. By trial design, we assume Assumption 2 for the RT data holds throughout the paper; however, we regard Assumption 3 for the RW data as an idealistic assumption, which may be violated. If Assumption 3 holds, we will use a semiparametric efficient strategy to combine both data sources for optimal estimation. However, if Assumption 3 is violated, our proposed method will automatically detect the violation and retain only the RT data for estimation.

Under Assumptions 1–3, the following identification formula holds for the HTE:

$$\mathbb{E} \left\{ \frac{AY}{e_\delta(X)} - \frac{(1-A)Y}{1-e_\delta(X)} \middle| Z, \delta \right\} = \tau(Z).$$

The identification formula motivates regression analysis based on the modified outcome $A\{e_\delta(X)\}^{-1}Y - (1 - A)\{1 - e_\delta(X)\}^{-1}Y$ to estimate the HTE. This approach involves the inverse of the treatment probability, and thus the resulting estimator may be unstable if some estimated treatment probabilities are close to zero or one. It calls for a principled way to construct improved estimators of the HTE. Toward this end, we derive the semiparametric efficiency score (SES) of the HTE under Assumptions 1–3 that motivates improved estimators.

2.3 Semiparametric efficiency score

The semiparametric model consists of model (1) with the parameter of interest ψ_0 and the unspecified distribution. Although Assumptions 1–3 do not have testable implications (except for the positivity of the propensity score), they impose restrictions on ψ_0 . To see this, define

$$H_\psi = Y - \tau_\psi(Z)A. \quad (2)$$

Intuitively, H_{ψ_0} subtracts from the subject’s observed outcome Y the treatment effect of the subject’s observed treatment $\tau_{\psi_0}(Z)A$, so it is mimicking the potential outcome $Y(0)$. Formally, following Robins (1994), we can show that $\mathbb{E}(H_{\psi_0} | A, X, \delta) = \mathbb{E}\{Y(0) | A, X, \delta\}$. Therefore, by Assumption 1, ψ_0 must satisfy the restriction:

$$\mathbb{E}(H_{\psi_0} | A, X, \delta) = \mathbb{E}(H_{\psi_0} | X, \delta). \quad (3)$$

For simplicity of exposition, denote

$$\mathbb{E}(H_{\psi_0} | X, \delta) = \mu_\delta(X), \quad \mathbb{V}(H_{\psi_0} | X, \delta) = \sigma_\delta^2(X),$$

where $\mu_\delta(X)$ is the outcome mean function and $\sigma_\delta^2(X)$ is the outcome variance function. By viewing (X, δ) jointly as the set of confounders, we invoke the SES of the structural nested mean model in Robins (1994). We further make a simplifying assumption that

$$\mathbb{E}(H_{\psi_0}^2 | A, X, \delta) = \mathbb{E}(H_{\psi_0}^2 | X, \delta), \quad (4)$$

which is a natural extension of (3). This assumption allows us to derive the SES of ψ_0 as

$$S_{\psi_0}(V) = q^*(X, \delta)\{H_{\psi_0} - \mu_\delta(X)\}\{A - e_\delta(X)\}, \quad q^*(X, \delta) = \{\partial\tau_{\psi_0}(Z)/\partial\psi\} \{\sigma_\delta^2(X)\}^{-1}, \quad (5)$$

which separates the term with the outcome, i.e., $H_{\psi_0} - \mu_\delta(X)$, and the term with the treatment, i.e., $A - e_\delta(X)$. This feature relaxes model assumptions of the nuisance functions while retaining root- n consistency in the estimation of ψ_0 ; see Section 2.4. Even without the simplifying assumption in (4), by the mean independence property in (3), we can verify that

$$\mathbb{E}\{S_{\psi_0}(V)\} = \mathbb{E}[q^*(X, \delta)\mathbb{E}\{H_{\psi_0} - \mu_\delta(X) \mid X, \delta\}] \times \mathbb{E}\{A - e_\delta(X) \mid X, \delta\} = 0.$$

Therefore, if (4) holds, $S_{\psi_0}(V)$ is the SES of ψ_0 ; if (4) does not hold, $S_{\psi_0}(V)$ is unbiased and permits robust estimation. Before delving into robust estimation in the next subsection, we provide examples to elucidate the SES below.

Example 3. *For a continuous outcome and the HTE function given in Example 1, the SES of ψ_0 is*

$$S_{\psi_0}(V) = Z \{\sigma_\delta^2(X)\}^{-1} \{H_{\psi_0} - \mu_\delta(X)\} \{A - e_\delta(X)\}.$$

For a binary outcome and the HTE function given in Example 2, the SES of ψ_0 is

$$S_{\psi_0}(V) = Z \frac{2 \exp(Z^\top \psi_0)}{\{\exp(Z^\top \psi_0) + 1\}^2} [\mu_\delta(X) \{1 - \mu_\delta(X)\}]^{-1} \{H_{\psi_0} - \mu_\delta(X)\} \{A - e_\delta(X)\}.$$

2.4 From SES to robust estimation

In principle, an efficient estimator for ψ_0 can be obtained by solving $\mathbb{P}_N S_{\text{eff}, \psi}(V) = 0$. However, $S_{\text{eff}, \psi}$ depends on the unknown distribution through $e_0(X)$, $\mu_\delta(X)$, and $\sigma_\delta^2(X)$, and thus solving $\mathbb{P}_N S_{\text{eff}, \psi}(V) = 0$ is infeasible. The state-of-art causal inference literature suggests that estimators constructed based on SES are robust to approximation errors using machine learning methods, the so-called rate double robustness; see, e.g., Chernozhukov et al. (2018), Rotnitzky et al. (2019).

In order to obtain a robust estimator with good efficiency properties, we consider approximating the unknown functions using non-parametric or machine learning methods. Our algorithm for the estimation of ψ_0 proceeds as follows.

Step 1. Obtain an estimator of $e_0(X)$ using non-parametric or machine learning methods, denoted by $\hat{e}_0(X)$, based on $\{(A_i, X_i, \delta_i = 0) : i \in \mathcal{B}\}$.

Step 2. Obtain a preliminary estimator $\hat{\psi}_p$ by solving $\sum_{i \in \mathcal{A}} [q^*(X_i, \delta_i) \{A_i - e_1(X_i)\} H_{\psi, i}] = 0$, based on $\{(A_i, X_i, Y_i, \delta_i = 1) : i \in \mathcal{A}\}$.

Step 3. Obtain the estimators of $\mu_1(X)$ and $\mu_0(X)$ using non-parametric or machine learning methods, denoted by $\hat{\mu}_1(X)$ and $\hat{\mu}_0(X)$, based on $\{(A_i, X_i, H_{\hat{\psi}_p, i}, \delta_i = 1) : i \in \mathcal{A}\}$ and $\{(A_i, X_i, H_{\hat{\psi}_p, i}, \delta_i = 0) : i \in \mathcal{B}\}$, respectively.

Step 4. Let $\widehat{S}_{\text{eff},\psi}(V)$ be $S_{\text{eff},\psi}(V)$ with the unknown quantities replaced by the estimated parametric models in Steps 1 and 3. Obtain the efficient integrative estimator $\widehat{\psi}_{\text{eff}}$ by solving

$$\mathbb{P}_N \widehat{S}_{\psi}(V) = 0. \quad (6)$$

The estimator $\widehat{\psi}_{\text{eff}}$ depends on the approximation of nuisance functions. To establish the asymptotic properties of $\widehat{\psi}_{\text{eff}}$, we provide the regularity conditions.

Assumption 4. (i) $\|\widehat{e}_0(X) - e_0(X)\| = o_{\mathbb{P}}(1)$ and $\|\widehat{\mu}_{\delta}(X) - \mu_{\delta}(X)\| = o_{\mathbb{P}}(1)$; (ii) $\|\widehat{e}_0(X) - e_0(X)\| \times \|\widehat{\mu}_{\delta}(X) - \mu_{\delta}(X)\| = o_{\mathbb{P}}(n^{-1/2})$; and (iii) additional regularity conditions in Assumption S1.

Assumption 4 is typical regularity conditions for Z-estimation or M-estimation (van der Vaart, 2000). Assumption 4 (i) states that we require that the posited models to be consistent for the two nuisance functions. Assumption 4 (ii) states that the *combined rate* of convergence of the posited models is of $o_{\mathbb{P}}(n^{-1/2})$. Assumption S1 regularizes the complexity of the functional space. Importantly, these conditions ensure $\widehat{\psi}_{\text{eff}}$ retains the parametric-rate consistency, allowing flexible data adaptive models and not restricting to stringent parametric models.

Theorem 1. *Suppose Assumptions 1–4 hold. Then, $\widehat{\psi}_{\text{eff}}$ is root- n consistent for ψ_0 and asymptotically normal.*

Theorem 1 implies that asymptotically, $\widehat{\psi}_{\text{eff}}$ can be viewed as the solution to $\mathbb{P}_N S_{\psi}(V) = 0$ when the nuisance functions are known. Therefore, for consistent variance estimation of $\widehat{\psi}_{\text{eff}}$, we can use the standard sandwich formula or the non-parametric bootstrap, treating the nuisance functions to be known.

3 Test-based elastic integrative analysis

A major concern for integrating the RT and RW data lies in the possibly poor quality of the RW data. For example, if the RW data did not capture all confounding variables, Assumption 3 is violated. Then, combining the RT and RW data into an integrative analysis would lead to a biased HTE estimator. In this section, we address the key challenge of preventing any biases present in the RW data to leak into the proposed estimator.

3.1 Detection of violation of the assumption required for the RW data

We consider all assumptions in Theorem 1 hold except that Assumption 3 may be violated. We derive a test that detects the violation of this key assumption for using the RW data. For simplicity, we denote the SES based solely on the RT or RW data as

$$S_{\text{rt},\psi}(V) = \delta S_{\psi}(V), \quad S_{\text{rw},\psi}(V) = (1 - \delta)S_{\psi}(V),$$

respectively. Moreover, let $\widehat{S}_{\text{rt},\psi}(V)$ and $\widehat{S}_{\text{rw},\psi}(V)$ be $S_{\text{rt},\psi}(V)$ and $S_{\text{rw},\psi}(V)$ with the nuisance functions replaced by their estimates, and let $\mathcal{I}_{\text{rt}} = \mathbb{E}\{S_{\text{rt},\psi_0}(V)^{\otimes 2} \mid \delta = 1\}$ and $\mathcal{I}_{\text{rw}} = \mathbb{E}\{S_{\text{rw},\psi_0}(V)^{\otimes 2} \mid \delta = 0\}$ be Fisher information matrices.

We now formulate the null hypothesis H_0 for the case when Assumption 3 holds and fixed and local alternatives H_a and $H_{a,n}$ for the case when Assumption 3 is violated:

$$H_0 \text{ (Null)} \quad \mathbb{E}\{S_{\text{rw},\psi_0}(V)\} = 0.$$

$$H_a \text{ (Fixed alternative)} \quad \mathbb{E}\{S_{\text{rw},\psi_0}(V)\} = \eta_{\text{fix}}, \text{ where } \eta_{\text{fix}} \text{ is a } p\text{-vector of constants with at least one non-zero component.}$$

$$H_{a,n} \text{ (Local alternative)} \quad \mathbb{E}\{S_{\text{rw},\psi_0}(V)\} = n^{-1/2}\eta, \text{ where } \eta \text{ is a } p\text{-vector of constants with at least one non-zero component.}$$

Considering the fix alternative is common to establish asymptotic properties of standard estimators and tests; however, the local alternative is useful to study finite-sample properties and regularity of non-standard estimators and tests. In finite samples, the violation of Assumption 3 may be weak; e.g., there exists a hidden confounder in the RW data, but the association between the hidden confounder and the outcome or the treatment is small. In these cases, in the local alternative $H_{a,n}$, the bias of $S_{\text{rw},\psi_0}(V)$ may be small, quantified by $n^{-1/2}\eta$. The values of η represent different tracks that the bias of $S_{\text{rw},\psi_0}(V)$ follows to coverage to zero. The local alternative encompasses the null and fixed alternative as special cases by considering different values of η . In particular, H_0 corresponds to $H_{a,n}$ with $\eta = 0$. Also, H_a corresponds to $H_{a,n}$ with $\eta = \pm\infty$; hence, considering H_a alone is not informative about the finite-sample behaviors of the proposed test and estimator.

Our detection of biases in the RW data is based on two key insights. First, we obtain an initial estimator $\widehat{\psi}_{\text{rt}}$ by solving the estimating equation based solely on the RT data, $\sum_{i \in \mathcal{A}} \widehat{S}_{\text{rt},\psi}(V_i) = 0$. It is important to emphasize that the propensity score in the RT, $e_1(X)$, is known by design, and therefore, $\widehat{\psi}_{\text{rt}}$ is always consistent. Second, if Assumption 3 holds

for the RW data, $S_{\text{rw},\psi_0}(V)$ is unbiased, but if it is violated, $S_{\text{rw},\psi_0}(V)$ is no longer unbiased. Therefore, large values of $n^{-1/2} \sum_{i \in \mathcal{B}} \widehat{S}_{\text{rw},\widehat{\psi}_{\text{rt}}}(V_i)$ provide evidence about the violation of Assumption 3.

To detect the violation of Assumption 3 for using the RW data, we construct the test statistic

$$T = \left\{ n^{-1/2} \sum_{i \in \mathcal{B}} \widehat{S}_{\text{rw},\widehat{\psi}_{\text{rt}}}(V_i) \right\}^{\text{T}} \widehat{\Sigma}_{SS}^{-1} \left\{ n^{-1/2} \sum_{i \in \mathcal{B}} \widehat{S}_{\text{rw},\widehat{\psi}_{\text{rt}}}(V_i) \right\}, \quad (7)$$

where $\Sigma_{SS} = \Gamma^{\text{T}} \mathcal{I}_{\text{rt}} \Gamma + \mathcal{I}_{\text{rw}}$ is the asymptotic variance of $n^{-1/2} \sum_{i \in \mathcal{B}} \widehat{S}_{\text{rw},\widehat{\psi}_{\text{rt}}}(V_i)$, $\Gamma = \mathcal{I}_{\text{rt}}^{-1} \mathcal{I}_{\text{rw}} \rho^{-1/2}$, and $\widehat{\Sigma}_{SS}$ is a consistent estimator for Σ_{SS} . The test statistic T measures the distance between $n^{-1/2} \sum_{i \in \mathcal{B}} \widehat{S}_{\text{rw},\widehat{\psi}_{\text{rt}}}(V_i)$ and zero. If the idealistic assumption holds, we expect T to be small. By the standard asymptotic theory, we show in the supplementary material that under H_0 , $T \sim \chi_p^2$, a Chi-square distribution with degrees of freedom p , a $n \rightarrow \infty$. This result serves as the basis for detecting the violation of the assumption required for the RW data.

3.2 Elastic integration

Let $c_\gamma = \chi_{p,\gamma}^2$ be the $(1 - \gamma)$ percentile of χ_p^2 . For a small γ , if $T \geq c_\gamma$, there is strong evidence to reject H_0 for the RW data; i.e., there is a detectable bias for the RW data estimator. In this case, we would only use the RT data for estimation. On the other hand, if $T < c_\gamma$, there is no strong evidence for the bias of the RW data estimator, and therefore, we would combine both the RT and RW data for optimal estimation. Our strategy leads to the elastic integrative estimator $\widehat{\psi}_{\text{elas}}$ solving

$$\sum_{i \in \mathcal{A} \cup \mathcal{B}} \left\{ \delta_i \widehat{S}_\psi(V_i) + \mathbf{1}(T < c_\gamma) (1 - \delta_i) \widehat{S}_\psi(V_i) \right\} = 0. \quad (8)$$

The choice of γ involves the bias-variance tradeoff. On the one hand, under H_0 , the acceptance probability of integrating the RW data is $\mathbb{P}(T < c_\gamma) = 1 - \gamma$. Therefore, for relatively large sample sizes, we will accept good-quality RW data with probability $1 - \gamma$ and reject good-quality RW data with type I error γ . On the other hand, under $H_{a,n}$, if η is small, the bias due to accepting the RW data is small compared to the increased variance due to rejecting the RW data, and hence small γ is desirable; while if η is large, the reverse is true and hence large γ is desirable.

To formally investigate the tradeoff, we characterize the asymptotic distributions of the elastic integrative estimator $\widehat{\psi}_{\text{elas}}$ under the null, fixed, and local alternatives. We do not discuss the trivial cases when $\gamma = 0$ and 1, corresponding to $\widehat{\psi}_{\text{elas}} = \widehat{\psi}_{\text{rt}}$ or $\widehat{\psi}_{\text{eff}}$. With $\gamma \in (0, 1)$, $\widehat{\psi}_{\text{elas}}$ mixes two distributions, namely, $\widehat{\psi}_{\text{rt}} \mid (T \geq c_\gamma)$ and $\widehat{\psi}_{\text{eff}} \mid (T < c_\gamma)$. Each

distribution is non-standard because the estimators and test are constructed based on the same data and therefore may be asymptotically dependent.

To characterize those non-standard distributions, we decompose this task into three steps. First, by the standard asymptotic theory, it follows that $T \sim \mathcal{Z}_1^\top \mathcal{Z}_1$, where \mathcal{Z}_1 is a standard p -variate normal random vector, $n^{1/2}(\widehat{\psi}_{\text{rt}} - \psi_0) \sim \mathcal{N}_{\text{rt}}$, and $n^{1/2}(\widehat{\psi}_{\text{eff}} - \psi_0) \sim \mathcal{N}_{\text{eff}}$, where \mathcal{N}_{rt} and \mathcal{N}_{eff} are some p -variate normal random vectors with variances $V_{\text{rt}} = (\rho \mathcal{I}_{\text{rt}})^{-1}$ and $V_{\text{eff}} = (\rho \mathcal{I}_{\text{rt}} + \mathcal{I}_{\text{rw}})^{-1}$, respectively.

Second, we find another standard p -variate normal random vector \mathcal{Z}_2 that is independent of \mathcal{Z}_1 , and decompose the normal distributions \mathcal{N}_{rt} and \mathcal{N}_{eff} into two orthogonal components: i) one corresponds to \mathcal{Z}_1 and ii) the other one corresponds to \mathcal{Z}_2 . Importantly, component i) would be affected by the test constraints induced by $\mathcal{Z}_1^\top \mathcal{Z}_1$, but component ii) would not be affected. For \mathcal{N}_{eff} , we show that it is fully represented by \mathcal{Z}_2 as $\mathcal{N}_{\text{eff}} = -V_{\text{eff}}^{1/2} \mathcal{Z}_2$. Therefore, its distribution is not affected by $\mathcal{Z}_1^\top \mathcal{Z}_1 < c_\gamma$; that is,

$$\mathcal{N}_{\text{eff}} \mid (\mathcal{Z}_1^\top \mathcal{Z}_1 < c_\gamma) \sim -V_{\text{eff}}^{1/2} \mathcal{Z}_2.$$

For \mathcal{N}_{rt} , we show that $\mathcal{N}_{\text{rt}} = V_{\text{rt-eff}}^{1/2} \mathcal{Z}_1 - V_{\text{eff}}^{1/2} \mathcal{Z}_2$ with $V_{\text{rt-eff}} = V_{\text{rt}} - V_{\text{eff}}$. Due to the independence between \mathcal{Z}_1 and \mathcal{Z}_2 , $\mathcal{N}_{\text{rt}} \mid (\mathcal{Z}_1^\top \mathcal{Z}_1 \geq c_\gamma)$ is a mixture distribution


$$\mathcal{N}_{\text{rt}} \mid (\mathcal{Z}_1^\top \mathcal{Z}_1 \geq c_\gamma) \sim V_{\text{rt-eff}}^{1/2} \mathcal{Z}_{c_\gamma}^{\text{t}} - V_{\text{eff}}^{1/2} \mathcal{Z}_2,$$

mixing a non-normal component, where \mathcal{Z}_c^{t} represents the truncated normal distribution $\mathcal{Z}_1 \mid (\mathcal{Z}_1^\top \mathcal{Z}_1 \geq c)$, and a normal component. For illustration, Figure 1 demonstrates the geometry of the decomposition of distributions with scalar variables.

Third, we formally characterize the distribution of \mathcal{Z}_c^{t} , a multivariate normal distribution with ellipsoid truncation (Tallis, 1963). This step enables us to quantify the asymptotic bias and variance of the proposed estimator; see Section 3.3.

Let $F_p(\cdot)$ be the cumulative distribution function (CDF) of a χ_p^2 random variable, and $F_p(\cdot; \lambda)$ be the CDF of a $\chi_p^2(\lambda)$ random variable, where χ_p^2 and $\chi_p^2(\lambda)$ are the central Chi-square distribution and the non-central Chi-square distribution with the non-centrality parameter λ , respectively. Theorem 2 summarizes the asymptotic distribution of $\widehat{\psi}_{\text{elas}}$.

Theorem 2. *Suppose assumptions in Theorem 1 hold except that Assumption 3 may be violated. Let \mathcal{Z}_1 and \mathcal{Z}_2 be independent normal random vectors with mean $\mu_1 = \Sigma_{SS}^{-1/2} \eta$ and $\mu_2 = V_{\text{eff}}^{1/2} \eta$, respectively, and covariance $I_{p \times p}$. Let \mathcal{Z}_c^{t} be the truncated normal distribution $\mathcal{Z}_1 \mid (\mathcal{Z}_1^\top \mathcal{Z}_1 \geq c)$. Let the elastic integrative estimator $\widehat{\psi}_{\text{elas}}$ be obtained by solving (8). Then,*



- $\mathcal{N}_{\text{rt}} = V_{\text{rt-eff}}^{1/2} \mathcal{Z}_1 - V_{\text{eff}}^{1/2} \mathcal{Z}_2$ and $\mathcal{N}_{\text{rt}} \mid (\mathcal{Z}_1^T \mathcal{Z}_1 \geq c_\gamma) \sim V_{\text{rt-eff}}^{1/2} \mathcal{Z}_1 \mid (\mathcal{Z}_1^T \mathcal{Z}_1 \geq c_\gamma) - V_{\text{eff}}^{1/2} \mathcal{Z}_2$
- $\mathcal{N}_{\text{eff}} = -V_{\text{eff}}^{1/2} \mathcal{Z}_2$ and $\mathcal{N}_{\text{eff}} \mid (\mathcal{Z}_1^T \mathcal{Z}_1 < c_\gamma) \sim \mathcal{N}_{\text{eff}}$

Figure 1: Representation of the normal distributions \mathcal{N}_{rt} and \mathcal{N}_{eff} based on \mathcal{Z}_1 and \mathcal{Z}_2 with $p = 1$

$n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)$ has a limiting mixture distribution

$$\mathcal{M}(\gamma; \eta) = \begin{cases} \mathcal{M}_1(\gamma; \eta) = V_{\text{rt-eff}}^{1/2} \mathcal{Z}_{c_\gamma}^t - V_{\text{eff}}^{1/2} \mathcal{Z}_2, & w.p. \xi, \\ \mathcal{M}_2(\eta) = -V_{\text{eff}}^{1/2} \mathcal{Z}_2, & w.p. 1 - \xi, \end{cases} \quad (9)$$

- Under H_0 , $\mu_1 = \mu_2 = 0$ and $\xi = 1 - F_p(c_\gamma) = \gamma$.
- Under H_a , $\mu_1 = \mu_2 = \pm\infty$ and $\xi = 1$; i.e., (9) reduces to a normal distribution with mean 0 and variance V_{rt} .
- Under $H_{a,n}$, $\mu_1 = \Sigma_{SS}^{-1/2} \eta$, $\mu_2 = V_{\text{eff}}^{1/2} \eta$ with $\eta \in \mathbb{R}^p$, and $\xi = 1 - F_p(c_\gamma; \lambda)$, where $\lambda = \eta^T \Sigma_{SS}^{-1} \eta$.

In Theorem 2, $\mathcal{M}(\gamma; \eta)$ in (9) a general characterization of the asymptotic distribution of $n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)$. It implies different asymptotic behaviors of $n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)$ depending on whether Assumption 3 is strongly, weakly or not violated. First, H_a corresponds to the situation where Assumption 3 is strongly violated. Under H_a , T rejects the RW data (i.e., $\mathcal{Z}_1^T \mathcal{Z}_1 \geq c_\gamma$ holds) with probability coverages to one, $\mathcal{Z}_{c_\gamma}^t$ becomes \mathcal{Z}_1 , and $\mathcal{M}(\gamma; \eta = \pm\infty)$ becomes $V_{\text{rt-eff}}^{1/2} \mathcal{Z}_1 - V_{\text{eff}}^{1/2} \mathcal{Z}_2$, a normal distribution with mean 0 and variance V_{rt} . As expected, under H_a , $n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)$ is asymptotically normal and regular. Second, H_0 and

$H_{a,n}$ correspond to the situations when Assumption 3 is not and weakly violated, respectively. Under H_0 and $H_{a,n}$, T has positive probabilities of accepting and rejecting the RW data, $\widehat{\psi}_{\text{elas}}$ switches between $\widehat{\psi}_{\text{eff}}$ and $\widehat{\psi}_{\text{rt}}$, and $n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)$ follows a limiting mixing distribution $\mathcal{M}(\gamma; \eta)$, indexed by η . Although the exact form of $\mathcal{M}(\gamma; \eta)$ is complicated, the entire distribution and summary statistics such as mean, variance and quantiles can be simulated by rejective sampling; see Section 3.4. Importantly, under H_0 and $H_{a,n}$, $n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)$ is non-normal and non-regular. The non-regularity is determined by the local parameter η , which entails that the asymptotic distribution of $n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)$ may change abruptly when H_0 is slightly violated. It is worth emphasizing that the local asymptotic provides a better approach to demonstrate the finite-sample properties of the test and estimators than the fix asymptotic does.

3.3 Asymptotic bias and MSE

Based on Theorem 2, it is important to understand the asymptotic behaviors of \mathcal{Z}_c^t and the truncated multivariate normal distribution in general. Toward that end, we derive the moment generating functions (MGFs) of such distributions in the supplementary material, which shed light on the moments of $n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)$.

Corollary 1 provides the analytical formula of the asymptotic bias and MSE of $n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)$.

Corollary 1. *Suppose assumptions in Theorem 1 hold except that Assumption 3 may be violated.*

- a) Under H_0 , the bias and MSE of $n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)$ are bias = 0 and mse = $V_{\text{eff}} + V_{\text{rt-eff}}\{1 + F_p(c_\gamma) - 2F_{p+2}(c_\gamma)\}$.
- b) Under H_a , the bias and MSE of $n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)$ are bias = 0 and mse = V_{rt} .
- c) Under $H_{a,n}$, the bias and MSE of $n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)$ are

$$\text{bias}(\gamma, \eta) = V_{\text{eff}}\eta\{F_p(c_\gamma; \lambda) - 2F_{p+2}(c_\gamma; \lambda)\}, \quad (10)$$

and

$$\begin{aligned} \text{mse}(\gamma, \eta) &= V_{\text{eff}} + V_{\text{rt-eff}}\{1 + F_p(c_\gamma; \lambda) - 2F_{p+2}(c_\gamma; \lambda)\} \\ &\quad + \eta V_{\text{eff}}^{\otimes 2} \eta^T \{F_p(c_\gamma; \lambda) - 2F_{p+2}(c_\gamma; \lambda)\}^2 \\ &\quad + \eta V_{\text{eff}}^{\otimes 2} \eta^T \{1 - F_p(c_\gamma; \lambda) + 4F_{p+2}(c_\gamma; \lambda) - 4F_{p+4}(c_\gamma; \lambda)\} \end{aligned} \quad (11)$$

$$-\eta V_{\text{eff}}^{\otimes 2} \eta^{\text{T}} \frac{\{1 + F_p(c_\gamma; \lambda) - 2F_{p+2}(c_\gamma; \lambda)\}^2}{1 - F_p(c_\gamma; \lambda)},$$

with $\lambda = \eta^{\text{T}} \Sigma_{SS}^{-1} \eta$.

Corollary 1 enables us to demonstrate the potential advantages and disadvantages of $\widehat{\psi}_{\text{elas}}$ compared with $\widehat{\psi}_{\text{rt}}$ and $\widehat{\psi}_{\text{eff}}$ under different scenarios.

- a) Under H_0 , because $1 + F_p(c_\gamma) - 2F_{p+2}(c_\gamma) \leq 1 - F_{p+2}(c_\gamma) \leq 1$ and hence $\mathbb{V}_a\{n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)\} \leq V_{\text{rt-eff}} + V_{\text{eff}} = V_{\text{rt}}$, $\widehat{\psi}_{\text{elas}}$ gains efficiency over $\widehat{\psi}_{\text{rt}}$, and the equality holds if and only if $\gamma = 0$ (i.e., $c_\gamma = 0$). Moreover, because $1 + \gamma - 2F_{p+2}(c_\gamma) \geq 0$ and hence $\mathbb{V}_a\{n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)\} \geq V_{\text{eff}}$, $\widehat{\psi}_{\text{elas}}$ loses efficiency compared with $\widehat{\psi}_{\text{eff}}$, and the equality holds if and only if $\gamma = 1$ (i.e., $c_\gamma = \infty$).
- b) Under H_a , $\widehat{\psi}_{\text{elas}}$ reduces to $\widehat{\psi}_{\text{rt}}$ in large samples, correspondingly $\mathbb{V}_a\{n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)\} = V_{\text{rt}}$.
- c) Under $H_{a,n}$, for a given $\gamma \in (0, 1)$, the bias and MSE of $\widehat{\psi}_{\text{elas}}$ increase with the local parameter η . If $\gamma = 0$ (implying $c_\gamma = \infty$ and $F_k(c_\gamma; \lambda) = 1$ for any integer k), $\widehat{\psi}_{\text{elas}}$ becomes $\widehat{\psi}_{\text{eff}}$ in large samples, and hence the asymptotic bias and MSE of $\widehat{\psi}_{\text{elas}}$ are $V_{\text{eff}}\eta$ and $V_{\text{eff}} + \eta V_{\text{eff}}^{\otimes 2} \eta^{\text{T}}$, which can be obtained by $\text{bias}(0, \eta)$ in (10) and $\text{mse}(0, \eta)$ in (11). If $\gamma = 1$ (implying $c_\gamma = 0$ and $F_k(c_\gamma; \lambda) = 0$ for any integer k), $\widehat{\psi}_{\text{elas}}$ becomes $\widehat{\psi}_{\text{rt}}$ in large samples, and hence the asymptotic bias and MSE of $\widehat{\psi}_{\text{elas}}$ are 0 and V_{rt} , which can be obtained by $\text{bias}(1, \eta)$ in (10) and $\text{mse}(1, \eta)$ in (11). This observation motivates our adaptive selection of γ in Section 3.6 in order to produce an elastic integrative estimator that has small bias and mean squared error for a possible value of η .

3.4 Illustration of the asymptotic distributions by rejective sampling

We can use rejective sampling to simulate the asymptotic distribution $\mathcal{M}(\gamma; \eta)$ of $n^{1/2}(\widehat{\psi}_{\text{elas}} - \psi_0)$. For illustration, consider scalar random variables \mathcal{Z}_1 and \mathcal{Z}_2 with $p = 1$, varying values of η , and $\mathcal{I}_{\text{rw}} = \mathcal{I}_{\text{rt}} = 1$. We simulate $\mathcal{Z}_{c_\gamma}^{\text{t}}$ by rejective sampling: draw values z^* from the standard normal distribution and only retain the values that satisfy $z^{*2} \geq c_\gamma$.

Figure 2 displays the limiting distributions with $\eta = 0$ corresponding to H_0 . Figure 2 (a) illustrates the mixture distribution $\mathcal{M}(\gamma; 0)$ and its two mixing components. Mixture.C1 is the mixing component $-V_{\text{rt-eff}}^{1/2} \mathcal{Z}_{c_\gamma}^{\text{t}} + V_{\text{eff}}^{1/2} \mathcal{Z}_2$, which centers at zero and has two modes. Mixture.C2 is the mixing component $V_{\text{eff}}^{1/2} \mathcal{Z}_2$, which centers at zero and is normally distributed. The mixture distribution mixes the two components which has lighter tails than







Figure 2: Illustration of the limiting distributions under H_0 . In both Panels (a) and (b), Mixture is $\mathcal{M}(\gamma; \eta = 0)$. In Panel (a): Mixture.C1 is the mixing component $-V_{\text{rt-eff}}^{1/2} \mathcal{Z}_{c_\gamma}^t + V_{\text{eff}}^{1/2} \mathcal{Z}_2$, and Mixture.C2 is the mixing component $V_{\text{eff}}^{1/2} \mathcal{Z}_2$. In Panel (b) N_{eff} is $V_{\text{eff}}^{1/2} \mathcal{Z}_2$, and N_{rt} is $V_{\text{rt}}^{1/2} \mathcal{Z}_1$. The value γ is 0.8. Panel (c) shows the mixture distributions with $\gamma = 1$ and $\rho \in \{0.1, 0.33, 0.5, 1\}$. Panel (d) shows the mixture distributions with $\rho = 1$ and $\gamma \in \{0.10, 0.25, 0.50, 0.90\}$.




(a) Mixing components.



(b) Mixture and normal distributions.



(c) Mixture distributions with ρ (rho).



(d) Mixture distributions with γ (gamma)

Figure 3: Illustration of the limiting distributions under $H_{a,n}$. In both Panels (a) and (b), Mixture is $\mathcal{M}(\gamma; \eta = 1)$. In Panel (a): Mixture.C1 is the mixing component $-V_{\text{rt-eff}}^{1/2} \mathcal{Z}_{c_\gamma}^t + V_{\text{eff}}^{1/2} \mathcal{Z}_2$, and Mixture.C2 is the mixing component $V_{\text{eff}}^{1/2} \mathcal{Z}_2$. In Panel (b) N_{eff} is $V_{\text{eff}}^{1/2} \mathcal{Z}_2$, and N_{rt} is $V_{\text{rt}}^{1/2} \mathcal{Z}_1$. The value γ is 0.8. Panel (c) shows the mixture distributions with $\gamma = 1$ and $\rho \in \{0.1, 0.33, 0.5, 1\}$. Panel (d) shows the mixture distributions with $\rho = 1$ and $\gamma \in \{0.10, 0.25, 0.50, 0.90\}$.

Mixture.C1 but heavier tails than Mixture.C2. Figure 2 (b) compares $\mathcal{M}(\gamma; 0)$ with \mathcal{N}_{eff} and \mathcal{N}_{rt} . It is clear that the variances decrease from \mathcal{N}_{rt} to $\mathcal{M}(\gamma; 0)$ and then to \mathcal{N}_{eff} . Moreover, the mixture distribution depends on some factors other than V_{eff} and V_{rt} including ρ and γ . Figure 2 (c) illustrates the mixture distribution with $\gamma = 0.8$ and $\rho \in \{0.1, 0.33, 0.5, 1\}$. As discussed before, ρ is the relative sample size of the RT data compared with the RW data. As ρ increases, the mixture distribution becomes narrower. Figure 2 (d) illustrates the mixture distribution with $\rho = 1$ and $\gamma \in \{0.10, 0.25, 0.50, 0.90\}$. As γ decreases, the mixture distribution becomes narrower. In this situation, a small value of γ is desirable.

Figure 3 displays the limiting distributions with $\eta = 1$ corresponding to $H_{a,n}$. Figure 3 (a) illustrates the mixture distribution $\mathcal{M}(\gamma; 1)$ and its two mixing components. Mixture.C1 and Mixture.C2 center at non-zero values. The mixture distribution mixes the two components and is non-normal. From Figure 3 (b), \mathcal{N}_{rt} is unbiased and \mathcal{N}_{eff} is biased, and $\mathcal{M}(\gamma; 1)$ reduces the bias of \mathcal{N}_{eff} . Figure 3 (c) illustrates the mixture distribution with $\gamma = 0.8$ and $\rho \in \{0.1, 0.33, 0.5, 1\}$. As ρ increases, the mixture distribution becomes narrower but bias increases. Figure 3 (d) illustrates the mixture distribution with $\rho = 1$ and $\gamma \in \{0.10, 0.25, 0.50, 0.90\}$. As γ decreases, the mixture distribution becomes narrower but is more biased. In this situation, a large value of γ is desirable.

3.5 Inference

The nonparametric bootstrap inference has been shown to be successful in many situations. However, it requires that the given estimator be smooth. This feature prevents the use of the nonparametric bootstrap inference for $\widehat{\psi}_{\text{elas}}$, because the indicator function in (8) renders $\widehat{\psi}_{\text{elas}}$ a non-smooth estimator (Shao, 1994). We formally show in the supplementary material that the inconsistency of the nonparametric bootstrap inference. Alternatively, Laber and Murphy (2011) proposed an adaptive confidence interval for the test error in classification, a non-regular statistics, by bootstrapping the upper and lower bounds of the test error. Similar to Laber and Murphy (2011), we propose an adaptive procedure for robust inference of ψ_0 accommodating the strength of violation of Assumption 3 in finite samples.

Let e_k be a p -vector of zeros except that the k th component is one, and let $e_k^T \psi_0$ be the k th component of ψ_0 , for $k = 1, \dots, p$. Because the asymptotic of $n^{1/2} e_k^T (\widehat{\psi}_{\text{elas}} - \psi_0)$ is different under the local and fixed alternatives, we propose different strategies of constructing CIs: under $H_{a,n}$, the asymptotic is non-standard, we construct a least favorable CI that guarantees good coverage properties uniformly over possible values of the local parameter η ; under H_a , the asymptotic is standard, we construct the usual Wald CI based on the normal limiting distribution.

First, under $H_{a,n}$, Assumption 3 is weakly violated and the strength of violation in finite samples is determined by the local parameter η . For a fixed η , let $\widehat{Q}_{k,\alpha}(\eta)$ be the approximated α -th quantile of $\mathcal{M}(\gamma; \eta)$, which can be obtained by rejective sampling. We can construct a $(1 - \alpha)$ confidence interval of $n^{1/2}e_k^T(\widehat{\psi}_{\text{elas}} - \psi_0)$ is $[\widehat{Q}_{k,\alpha/2}(\eta), \widehat{Q}_{k,1-\alpha/2}(\eta)]$. Different CIs are required for different values of η . To accommodate different possible values of η , one solution is to construct the least favorable CI by taking the infimum of the lower bound of the CI $\widehat{Q}_{k,\alpha/2}(\eta)$ and the supremum of the upper bound of the CI $\widehat{Q}_{k,1-\alpha/2}(\eta)$ over all possible values of η . However, the range of η can be very wide, rendering the least favorable CI non-informative. We identify that the plausible values of η following a multivariate normal distribution with mean $n^{-1/2} \sum_{i \in \mathcal{B}} \widehat{S}_{\text{rw}, \widehat{\psi}_{\text{rt}}}(V_i)$ and variance $\widehat{\Sigma}_{SS}$. Let $\tilde{\alpha} = 1 - (1 - \alpha)^{1/2}$, such that $(1 - \tilde{\alpha})^2 = 1 - \alpha$, and let $\mathcal{B}_{1-\tilde{\alpha}}$ be a bounded region of η with probability $1 - \tilde{\alpha}$. We construct the $(1 - \alpha)$ least favorable CI for $n^{1/2}e_k^T(\widehat{\psi}_{\text{elas}} - \psi_0)$ as $[\inf_{\eta \in \mathcal{B}_{1-\tilde{\alpha}}} \widehat{Q}_{k,\tilde{\alpha}/2}(\eta), \sup_{\eta \in \mathcal{B}_{1-\tilde{\alpha}}} \widehat{Q}_{k,1-\tilde{\alpha}/2}(\eta)]$. Here, using the wider $(1 - \tilde{\alpha})$ quantile range of $\widehat{Q}_k(\eta)$ instead of the $(1 - \alpha)$ quantile range is necessary to guarantee the coverage of $(1 - \alpha)$ due to ignoring other possible values of η outside $\mathcal{B}_{1-\tilde{\alpha}}$.

Second, under H_a , Assumption 3 is strongly violated. As shown in Theorem 2, $n^{1/2}e_k^T(\widehat{\psi}_{\text{elas}} - \psi_0)$ is regular and asymptotically normal, denoted by $\mathcal{M}(\gamma; \pm\infty)$. Therefore, a $(1 - \alpha)$ confidence interval of $n^{1/2}e_k^T(\widehat{\psi}_{\text{elas}} - \psi_0)$ can be constructed based on the $\alpha/2$ - and $(1 - \alpha/2)$ -th quantiles of the normal distribution $\mathcal{M}(\gamma; \pm\infty)$, denoted by $[\widehat{Q}_{k,\alpha/2}(\pm\infty), \widehat{Q}_{k,1-\alpha/2}(\pm\infty)]$.

Finally, because the least favorable CI may be unnecessarily wide under H_a , we require a strategy to distinguish between $H_{a,n}$ corresponding to finite values of η and H_a corresponding to $\eta = \pm\infty$. To do this, we use the test statistic T . Under $H_{a,n}$, $T = O_{\mathbb{P}}(1)$; while under H_a , $T = \infty$. Therefore, we specify a sequence of thresholds $\{\kappa_n : n \geq 1\}$ that diverges to infinity as $n \rightarrow \infty$ and compare T to κ_n . Many choices of κ_n can be considered, e.g., $\kappa_n = \{\log(n)\}^{1/2}$ which is similar to the BIC criteria (Cheng, 2008, Andrews and Soares, 2010). If $T \leq \kappa_n$, we choose the local alternative strategy to construct the least favorable CI, and if $T > \kappa_n$, we choose the fix alternative strategy to construct a normal CI, leading to an elastic CI

$$\text{ECI}_{k,1-\alpha} = \begin{cases} [\inf_{\eta \in \mathcal{B}_{1-\tilde{\alpha}}} \widehat{Q}_{k,\tilde{\alpha}/2}(\eta), \sup_{\eta \in \mathcal{B}_{1-\tilde{\alpha}}} \widehat{Q}_{k,1-\tilde{\alpha}/2}(\eta)], & \text{if } T \leq \kappa_n, \\ [\widehat{Q}_{k,\alpha/2}(\pm\infty), \widehat{Q}_{k,1-\alpha/2}(\pm\infty)], & \text{if } T > \kappa_n. \end{cases} \quad (12)$$

Theorem 3. *Suppose assumptions in Theorem 1 hold except that Assumption 3 may be violated. The asymptotic coverage rate of the elastic CI of $n^{1/2}e_k^T(\widehat{\psi}_{\text{elas}} - \psi_0)$ in (12) satisfies*

$$\lim_{n \rightarrow \infty} \mathbb{P} \left\{ n^{1/2}e_k^T(\widehat{\psi}_{\text{elas}} - \psi_0) \in \text{ECI}_{k,1-\alpha} \right\} \geq 1 - \alpha,$$

and the equality holds under H_a .

3.6 Adaptive selection of γ

The selection of γ involves the bias-variance tradeoff and therefore is important to determine the MSE of $\widehat{\psi}_{\text{elas}}$. Corollary 1 indicates that under $H_{a,n}$, the MSE of $\widehat{\psi}_{\text{elas}}$ in (11) involves two terms: Term 1 is $V_{\text{eff}} + V_{\text{rt-eff}}\{1 + F_p(c_\gamma; \lambda) - 2F_{p+2}(c_\gamma; \lambda)\}$, and remaining Term 2 involving $\eta V_{\text{eff}}^{\otimes 2} \eta^\top$. If η is small, the MSE is dominated by Term 1, which can be made small if we select a small γ ; while if η is large, the MSE is dominated by Term 2, which can be made small if we select a large γ .

The above observation motivates an adaptive selection of γ . We propose to estimate η by $\widehat{\eta} = n^{-1/2} \sum_{i \in \mathcal{B}} \widehat{S}_{\text{rw}, \widehat{\psi}_{\text{rt}}}(V_i)$ and select γ that minimizes $\text{mse}(\gamma; \widehat{\eta})$, where $\text{mse}(\gamma; \eta)$ is given by (11) or approximated by rejective sampling. In practice, we can specify a grid of values from 0 to 1 for γ , denoted by \mathcal{G} , simulate the distribution of $\mathcal{M}(\gamma; \widehat{\eta})$ for all $\gamma \in \mathcal{G}$, and finally choose γ to be the one in \mathcal{G} that minimizes the MSE of $\mathcal{M}(\gamma; \widehat{\eta})$. As corroborated by simulation, the selection strategy is effective in the sense that when the signal of violation is weak, the selected value of γ is small and when the signal of violation is strong, the selected value of γ is large.

4 Simulation

We evaluate the finite sample performance of the proposed elastic estimator via simulation for the robustness against unmeasured confounding and the adaptive inference. Specifically, we compare the RT estimator, the efficient combining estimator, and the elastic estimator under settings that vary the strength of unmeasured confounding in the RW data.

We first generate populations of size 10^5 . For each population, we generate the covariate $X = (1, X_1, X_2, X_3)^\top$, where $X_j \sim \text{Normal}(0, 1)$ for $j = 1, 2, 3$, and the treatment effect modifier is $Z = (1, X_1, X_2)^\top$. We generate $Y(a)$ by

$$\begin{aligned} Y(a) \mid X &= \mu(X; b) + a \times \tau(Z) + \epsilon(a), \\ \mu(X; b) &= X_1 + bX_3, \\ \tau(Z) &= \psi_1 + \psi_2 X_1 + \psi_3 X_2, \\ \epsilon(a) &\sim \text{Normal}(0, 1), \end{aligned} \tag{13}$$

for $a = 0, 1$. Throughout the simulation, the parameter of interest $\psi = (\psi_1, \psi_2, \psi_3)^\top = (1, 1, 1)^\top$ is fixed; however, we vary b to indicate the different strengths of unmeasured con-

founding in the analysis (violation of Assumption 3). We then generate two samples from the target population. We generate the RT selection indicator by $\delta | X \sim \text{Bernoulli}\{\pi_\delta(X)\}$, where $\text{logit}\{\pi_\delta(X)\} = -6.5 + X_1 + X_2$. Under this selection mechanism, the selection rate is around 0.3%, which results in $n \approx 300$ RT subjects, similar to the CALGB 9633 trial in the motivating application. We also take a random sample of size $m = 1000$ from the population to form a RW sample. In the RT sample, the treatment assignment is $A | X, \delta = 1 \sim \text{Bernoulli}\{e_1(X)\}$, where $e_1(X) = 0.5$. In the RW sample, $A | X, \delta = 0 \sim \text{Bernoulli}\{e_0(X)\}$, where $\text{logit}\{e_0(X)\} = 1 - 2X_1 - 2X_3$. The observed outcome Y in both samples is $Y = AY(1) + (1 - A)Y(0)$.

To assess the robustness of the elastic integrative estimator against unmeasured confounding, we consider the omission of X_3 in all estimators, resulting in unmeasured confounding in the RW data. The strength of unmeasured confounding is indexed by b in (13); high values of b indicate strong levels of unmeasured confounding and vice versa. We specify the range of b by exponentiating seven values in a regular grid from 3 to 5 and dividing by $m^{1/2}$, i.e., $b \in \{0.10, 0.17, 0.29, 0.51, 0.89, 1.54, 2.69\}$. We compare the following estimators for the HTE parameter ψ_0 :

- a) $\hat{\psi}_{\text{rt}}$: the covariate adjustment approach of Tian et al. (2014) that fits Y_i against the adjusted covariate $(A_i - 0.5)Z_i$ based only on the RT data;
- b) $\hat{\psi}_{\text{eff}}$: the efficient integrative estimator solving (6);
- c) $\hat{\psi}_{\text{elas}}$: the proposed elastic integrative estimator solving (8) with adaptive selection of γ .

For $\hat{\psi}_{\text{eff}}$ and $\hat{\psi}_{\text{elas}}$, we estimate the propensity score function by a logistic sieve model with the power series X , X^2 and their two-way interactions (omitting X_3) and the outcome mean function by a linear sieve model with the power series X , X^2 and their two-way interactions (omitting X_3). The CIs are constructed for $\hat{\psi}_{\text{rt}}$ and $\hat{\psi}_{\text{eff}}$ based on the nonparametric bootstrap with the bootstrap size 100 and for $\hat{\psi}_{\text{elas}}$ based on the elastic approach with $\kappa_m = \{\log(m)\}^{1/2}$.

Figure 4 presents the violin plots based on 2000 simulated datasets. Each column of the plots corresponds to a different strength of unmeasured confounding indexed by b . Table 1 reports the coverage rates of 95% CIs, the ratios of the MSE of the estimator and the MSE of $\hat{\psi}_{\text{rt}}$, and the selected γ . The covariate adjustment estimator based only on the RT data $\hat{\psi}_{\text{rt}}$ is unbiased across different scenarios, and the coverage rates are close to the nominal level. However, the variability of $\hat{\psi}_{\text{rt}}$ is large, due to the small sample size of the RT sample. The efficient integrative estimator $\hat{\psi}_{\text{eff}}$ gains efficiency over $\hat{\psi}_{\text{rt}}$ by leveraging the large sample size of the RW data. However, the bias of $\hat{\psi}_{\text{eff}}$ increases and the coverage rate is more off the




Figure 4: Violin plots of estimators of $\psi^T = (\psi_1, \psi_2, \psi_3)$ subtracting the true values varying the strength of unmeasured confounding. In each plot, the three estimators $\hat{\psi}_{rt}$, $\hat{\psi}_{eff}$, and $\hat{\psi}_{elas}$ are labeled by “rt”, “eff”, and “elas”, respectively. Each column of the plots corresponds to a different strength of unmeasured confounding labeled by “b”; each row of the plots corresponds to a different component of ψ : “psi: 1” for ψ_1 , “psi: 2” for ψ_2 , “psi: 3” for ψ_3 .

Table 1: Simulation results for coverage rates of 95% confidence interval and ratio $\times 10^2$ of MSE of the estimator and MSE of $\hat{\psi}_{rt}$

| b | Coverage rate | | | | | | | | | Ratio of MSEs | | | | | | γ |
|------|---------------|----------|----------|----------|----------|----------|----------|----------|----------|---------------|----------|----------|----------|----------|----------|----------|
| | RT | | | Eff | | | Elastic | | | Eff | | | Elastic | | | |
| | ψ_1 | ψ_2 | ψ_3 | ψ_1 | ψ_2 | ψ_3 | ψ_1 | ψ_2 | ψ_3 | ψ_1 | ψ_2 | ψ_3 | ψ_1 | ψ_2 | ψ_3 | |
| 0.1 | 94.1 | 94.8 | 93.5 | 94.1 | 94.7 | 94.8 | 95.1 | 96.4 | 96.7 | 3 | 4 | 4 | 10 | 6 | 8 | 0.13 |
| 0.17 | 94.3 | 94.9 | 93.8 | 92.1 | 94.5 | 95.1 | 94.2 | 96.6 | 96.3 | 3 | 4 | 4 | 11 | 6 | 8 | 0.13 |
| 0.29 | 94.9 | 94.9 | 93.9 | 80.7 | 94.3 | 92.8 | 93.3 | 96.0 | 95.7 | 6 | 4 | 5 | 14 | 6 | 9 | 0.15 |
| 0.51 | 94.9 | 95.0 | 94.0 | 19.6 | 89.9 | 86.3 | 91.5 | 94.3 | 93.4 | 26 | 5 | 6 | 31 | 9 | 14 | 0.33 |
| 0.89 | 95.1 | 95.7 | 94.2 | 0.0 | 74.6 | 59.0 | 95.5 | 93.6 | 92.1 | 142 | 12 | 17 | 51 | 14 | 26 | 0.82 |
| 1.54 | 95.3 | 95.7 | 94.0 | 0.0 | 48.9 | 14.0 | 95.2 | 94.4 | 93.2 | 547 | 26 | 60 | 55 | 19 | 36 | 0.82 |
| 2.69 | 95.7 | 95.3 | 93.6 | 0.0 | 31.4 | 0.8 | 94.5 | 94.5 | 93.5 | 1289 | 41 | 163 | 78 | 27 | 48 | 0.88 |

Table 2: Covariate means by treatment group in the CALGB 9633 trial sample and the NCDB sample.

| | N | A | age (years) | tumor size (cm) | male (y/n) | squamous (y/n) | white (y/n) |
|----------------|-------|-------|----------------|--------------------|---------------|-------------------|----------------|
| RT: CALGB 9633 | 156 | $A=1$ | 60.6 | 4.62 | 64.1% | 40.4% | 90.4% |
| | 163 | $A=0$ | 61.1 | 4.57 | 63.8% | 39.3% | 88.3% |
| RW: NCDB | 4263 | $A=1$ | 63.9 | 5.19 | 54.3% | 35.6% | 88.6% |
| | 10903 | $A=0$ | 69.4 | 4.67 | 54.8% | 40.5% | 90.0% |

nominal level as b increases. As shown by the ratios of the MSE of $\hat{\psi}_{\text{eff}}$ and the MSE of $\hat{\psi}_{\text{rt}}$, for small values of b , the ratio is smaller than one due to the small bias and small variance of $\hat{\psi}_{\text{eff}}$; while for large values of b , the ratio is larger than one due to the large bias of $\hat{\psi}_{\text{elas}}$. The elastic integrative estimator $\hat{\psi}_{\text{elas}}$ with the adaptive selection of γ has small biases across all scenarios regardless of the strength of unmeasured confounding. As demonstrated in the last column of Table 1, the selected γ increases as b increases, which show the proposed adaptive selection strategy is effective. Moreover, compared with $\hat{\psi}_{\text{rt}}$, $\hat{\psi}_{\text{elas}}$ has smaller variances and MSEs by integrating the RW data across all scenarios, suggesting that the integration of the RW data is beneficial to improve estimation efficiency. The coverage rates of the elastic CIs are all close to the nominal level for all settings with different values of b .

5 Application

We illustrate the potential benefit of the proposed elastic estimator to evaluate the effect of adjuvant chemotherapy for early-stage resected non-small cell lung cancer (NSCLC) using the CALGB 9633 data and a large clinical oncology database, the NCDB. In CALGB 9633, we include 319 patients with 163 randomly assigned to observation ($A = 0$) and 156 randomly assigned to chemotherapy ($A = 1$). The comparable sample from the NCDB includes 15337 patients diagnosed with NSCLC between years 2004 – 2016 in stage IB disease with 11021 on observation and 4316 received chemotherapy after surgery. The numbers of treated and controls are relatively balanced in the CALGB 9633 trial while they are unbalanced in the NCDB. We include five covariates in the analysis: gender (1 = male, 0 = female), age, indicator for histology (1 = squamous, 0 = non-squamous), race (1 = white, 0 = non-white), and tumor size in cm. The outcome is the indicator of cancer recurrence within 3 years after the surgery, i.e. $Y = 1$ if recurrence occurred and $Y = 0$ otherwise.

Table 2 reports the covariate means by treatment group in the two samples. Due to treatment randomization, covariates are balanced between the treated and the control in the




Figure 5: Estimated treatment effect as a function of the (standardized) tumor size along with the 95% Wald confidence intervals: $\text{tumor size}^* = (\text{tumor size} - 4.82) / 1.72$

CALGB 9633 trial sample. While due to lack of treatment randomization, covariates are highly unbalanced in the NCDB sample. It can be seen that older patients with histology and smaller tumor size are likely to choose a conservative treatment, on observation. Moreover, we can not rule out the possibility of unmeasured confounders in the NCDB sample.

We assume a linear HTE function with tumor size as the treatment effect modifier. We compare the same set of estimators and variance estimators considered in the simulation study. Table 3 reports the results. Figure 5 shows the estimated treatment effect as a function of the standardized tumor size. Due to the limited sample size of the trial sample, all components in $\hat{\psi}_{\text{covj,rt}}$ are not significant. By directly combining the trial sample and the NCDB sample, $\hat{\psi}_{\text{eff}}$ reveals that adjuvant chemotherapy significantly in reducing cancer recurrence within 3 years after the surgery, and patients with larger tumor sizes benefit more from adjuvant chemotherapy. But this finding may be subject to unmeasured confounding biases of the NCDB sample. In the proposed elastic integrative analysis, the test statistic is $T = 1.9$, and hence there is no strong evidence that the NCDB presents hidden confounding in our analysis. As a result, the elastic integrative estimator $\hat{\psi}_{\text{elas}}$ remains the same as $\hat{\psi}_{\text{eff}}$. In reflection of the pre-testing procedure, the estimated standard error of $r \hat{\psi}_{\text{elas}}$ is larger than that of $\hat{\psi}_{\text{eff}}$. From Figure 5, patients with tumor sizes in $[4.82 + 1.72 \times (-0.67), 4.82 + 1.72 \times (2.18)] = [3.67, 8.57]$ significantly benefit from adjuvant adjuvant chemotherapy in

Table 3: Point estimate, standard error and 95% Wald confidence interval of the causal risk difference between adjuvant chemotherapy and observation based on the CALGB 9633 trial sample and the NCDB sample: tumor size* = (tumor size - 4.82)/1.72

| | Intercept ($\psi_{0,1}$) | | | tumor size* ($\psi_{0,2}$) | | |
|------|----------------------------|--------|------------------|------------------------------|-------|------------------|
| | Est. | S.E. | C.I. | Est. | S.E. | C.I. |
| rt | -0.094 | 0.054 | (-0.202, 0.015) | 0.002 | 0.055 | (-0.107, 0.111) |
| eff | -0.076 | 0.0083 | (-0.093, -0.059) | -0.026 | 0.009 | (-0.043, -0.009) |
| elas | -0.076 | 0.0196 | (-0.115, -0.037) | -0.026 | 0.029 | (-0.084, 0.032) |

reducing cancer recurrence within 3 years after the surgery.

6 Concluding remarks

The proposed elastic estimator integrates “high-quality small data” with “big data” to simultaneously leverage small but carefully controlled unbiased experiments and massive but possibly biased RW datasets for HTEs. Most of causal inference methods require the no unmeasured confounding assumption. However, this assumption may not hold for the RW data due to the uncontrolled real-world data collection mechanism and is unverifiable based only on the RW data. Utilizing the design advantage of RTs, we are able to gauge the reliability of the RW data and decide whether or not to use RW data in an integrative analysis. The elastic integrative estimator gains efficiency over the RT-only estimator by integrating the reliable RW data with good quality and also automatically detects the existence of bias in the RW data and gears to the RT data. The proposed estimator is non-regular and belongs to pre-test estimation by construction (Giles and Giles, 1993). To demonstrate the non-regularity issue, we characterize the distribution of the elastic integrative estimator under local alternatives, which provide better approximation of the finite-sample behaviors. Moreover, we provide data adaptive selection of the threshold in the testing procedure which guarantees small MSE of the estimator and elastic confidence intervals which are valid under all hypotheses H_0 , $H_{a,n}$ and H_a .

We have assumed that the treatment effect function is correctly specified. In future work, we will derive tests based on over-identification restrictions tests (Yang and Lok, 2016) for evaluating a treatment effect model. Moreover, to evaluate the treatment effect modifications of adjuvant chemotherapy, the set of treatment effect modifiers are suggested based on subject matter knowledge. Without such knowledge, it is important to identify the true treatment effect modifiers among a set of variables. We will develop a variable selection procedure for identifying effect modifiers. The insight is that we can create a larger number

of estimating functions than the number of parameters. The problem for effect modifiers selection falls into the recent work of Chang et al. (2017) on high-dimensional statistical inferences with over-identification.

The current framework allows the outcome to be continuous or binary. In cancer clinical trials, survival outcomes are most common. Following Yang (2018), we will consider the structural failure time model for the HTE that specifies the relationship of the potential baseline failure time $T(0)$ and the actual observed failure time T . We assume that, given any X , $T(0) \sim T \exp\{A\tau_{\psi_0}(X)\}$, where \sim means “has the same distribution as.” This model entails that the treatment effect is to accelerate or decelerate the failure time compared to the baseline failure time $T(0)$. Intuitively, $\exp\{A\tau_{\psi_0}(X)\}$ describes the relative increase/decrease in the failure time had the patient received treatment compared to had the treatment always been withheld and the effect rate of the treatment can possibly be modified by $\tau_{\psi_0}(X)$. Then, we define H_ψ in (2) as $H_\psi = T \exp\{A\tau_\psi(X)\}$ to mimic the baseline failure time $T(0)$. A unique challenge in the survival outcome setting is the possibility of censoring which prevents observing all T 's. In our future work, we will develop elastic algorithms to combine the RT and RW data for right-censored survival outcome.

Because the RW data were not collected for research purposes, data quality may be poor such as measurement errors and missingness. Moreover, data collected from RTs may not be available in RW data or vice versa, resulting in data structure misalignment (Li et al., 2020). Developing principled methods to deal with these practical issues will be our future work.

Supplementary material

Supplementary material online includes technical details and proofs.

References

- Andrews, D. W. and Soares, G. (2010). Inference for parameters defined by moment inequalities using generalized moment selection, *Econometrica* **78**: 119–157.
- Bickel, P. J., Klaassen, C., Ritov, Y. and Wellner, J. (1993). *Efficient and Adaptive Inference in Semiparametric Models*, Johns Hopkins University Press, Baltimore.
- Buchanan, A. L., Hudgens, M. G., Cole, S. R., Mollan, K. R., Sax, P. E., Daar, E. S., Adimora, A. A., Eron, J. J. and Mugavero, M. J. (2018). Generalizing evidence from

- randomized trials using inverse probability of sampling weights, *Journal of the Royal Statistical Society: Series A (Statistics in Society)* **181**: 1193–1209.
- Chakraborty, B. and Moodie, E. E. (2013). *Statistical methods for dynamic treatment regimes*, Springer, New York.
- Chang, J., Tang, C. Y. and Wu, T. T. (2017). A new scope of penalized empirical likelihood with high-dimensional estimating equations, *arXiv preprint arXiv:1704.00566* .
- Cheng, X. (2008). Robust confidence intervals in nonlinear regression under weak identification, *Manuscript, Department of Economics, Yale University* .
- Chernozhukov, V., Chetverikov, D., Demirer, M., Duflo, E., Hansen, C., Newey, W. and Robins, J. (2018). Double/debiased machine learning for treatment and structural parameters, *The Econometrics Journal* **21**: 1–68.
- Dahabreh, I. J., Robertson, S. E., Tchetgen, E. J. T., Stuart, E. A. and Hernán, M. A. (2018). Generalizing causal inferences from individuals in randomized trials to all trial-eligible individuals, *Biometrics*: 10.1111/biom.13009 .
- Giles, J. A. and Giles, D. E. (1993). Pre-test estimation and testing in econometrics: recent developments, *Journal of Economic Surveys* **7**: 145–197.
- Hamburg, M. A. and Collins, F. S. (2010). The path to personalized medicine, *N Engl J Med* **363**: 301–304.
- Laber, E. B. and Murphy, S. A. (2011). Adaptive confidence intervals for the test error in classification, *J Am Stat Assoc* **106**: 904–913.
- Le Chevalier, T. (2003). Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): Cisplatin-based chemotherapy (CT) vs no CT in 1867 patients with resected non-small cell lung cancer (NSCLC), **21**: 238–238.
- Li, H., Miao, W., Cai, Z., Liu, X., Zhang, T., Xue, F. and Geng, Z. (2020). Causal data fusion methods using summary-level statistics for a continuous outcome, *Stat Med* **39**(8): 1054–1067.
- Morgensztern, D., Du, L., Waqar, S. N., Patel, A., Samson, P., Devarakonda, S., Gao, F., Robinson, C. G., Bradley, J. and Baggstrom, M. (2016). Adjuvant chemotherapy for patients with T2N0M0 NSCLC, *Journal of Thoracic Oncology* **11**: 1729–1735.

- Neyman, J. (1923). Sur les applications de la thar des probabilities aux experiences Agaricales: Essay de principe. English translation of excerpts by Dabrowska, D. and Speed, T., *Statistical Science* **5**: 465–472.
- Norris, S., Atkins, D., Bruening, W., Fox, S., Johnson, E., Kane, R., Morton, S. C., Oremus, M., Ospina, M., Randhawa, G., Schoelles, K., Shekelle, P. and Viswanathan, M. (2010). Selecting observational studies for comparing medical interventions, *Methods guide for effectiveness and comparative effectiveness reviews [Internet]*, Agency for Healthcare Research and Quality (US).
- Prentice, R. L., Langer, R., Stefanick, M. L., Howard, B. V., Pettinger, M., Anderson, G., Barad, D., Curb, J. D., Kotchen, J. and Kuller, L. (2005). Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the women’s health initiative clinical trial, *Am J Epidemiol* **162**: 404–414.
- Richardson, T. S., Robins, J. M. and Wang, L. (2017). On modeling and estimation for the relative risk and risk difference, *J Am Stat Assoc* **112**: 1121–1130.
- Robins, J. M. (1994). Correcting for non-compliance in randomized trials using structural nested mean models, *Communications in Statistics-Theory and Methods* **23**: 2379–2412.
- Rothwell, P. M. (2005). Subgroup analysis in randomised controlled trials: importance, indications, and interpretation, *The Lancet* **365**: 176–186.
- Rothwell, P. M., Mehta, Z., Howard, S. C., Gutnikov, S. A. and Warlow, C. P. (2005). From subgroups to individuals: general principles and the example of carotid endarterectomy, *The Lancet* **365**: 256–265.
- Rotnitzky, A., Smucler, E. and Robins, J. M. (2019). Characterization of parameters with a mixed bias property, *arXiv preprint arXiv:1904.03725* .
- Rubin, D. B. (1974). Estimating causal effects of treatments in randomized and nonrandomized studies, *Journal of Educational Psychology* **66**: 688–701.
- Shao, J. (1994). Bootstrap sample size in nonregular cases, *Proc Amer Math Soc* **122**: 1251–1262.
- Sherman, R. E., Anderson, S. A., Dal Pan, G. J., Gray, G. W., Gross, T., Hunter, N. L., LaVange, L., Marinac-Dabic, D., Marks, P. W., Robb, M. A., Shuren, J., Temple, R.,

- Woodcock, J., Yue, L. and Califf, R. (2016). Real-world evidence—what is it and what can it tell us, *New England Journal of Medicine* **375**(23): 2293–2297.
- Shi, C., Song, R. and Lu, W. (2016). Robust learning for optimal treatment decision with np-dimensionality, *Electronic Journal of Statistics* **10**: 2894–2921.
- Speicher, P. J., Englum, B. R., Ganapathi, A. M., Mulvihill, M. S., Hartwig, M. G., Onaitis, M. W., D’Amico, T. A. and Berry, M. F. (2015). Adjuvant chemotherapy is associated with improved survival after esophagectomy without induction therapy for node-positive adenocarcinoma, *Journal of Thoracic Oncology* **10**: 181–188.
- Staiger, D. and Stock, J. H. (1997). Instrumental variables regression with weak instruments, **65**: 557–586.
- Strauss, G. M., Herndon, J. E., II, M. A. M., Johnstone, D. W., Johnson, E. A., Harpole, D. H., Gillenwater, H. H., Watson, D. M., Sugarbaker, D. J. and Schilsky, R. L. (2008). Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups, *Journal of Clinical Oncology* **26**: 5043.
- Stuart, E. A., Cole, S. R., Bradshaw, C. P. and Leaf, P. J. (2011). The use of propensity scores to assess the generalizability of results from randomized trials, *Journal of the Royal Statistical Society: Series A (Statistics in Society)* **174**: 369–386.
- Tallis, G. (1963). Elliptical and radial truncation in normal populations, *The Annals of Mathematical Statistics* **34**: 940–944.
- Tian, L., Alizadeh, A., Gentles, A. and Tibshirani, R. (2014). A simple method for estimating interactions between a treatment and a large number of covariates, *J Am Stat Assoc* **109**: 1517–1532.
- Toyoda, T. and Wallace, T. D. (1979). Pre-testing on part of the data, *Journal of Econometrics* **10**: 119–123.
- van der Vaart, A. W. (2000). *Asymptotic Statistics*, Cambridge University Press, Cambridge, MA.
- Verde, P. E. and Ohmann, C. (2015). Combining randomized and non-randomized evidence in clinical research: a review of methods and applications, *Research Synthesis Methods* **6**: 45–62.

- Yang, S. (2018). Semiparametric efficient estimation of structural nested mean models with irregularly spaced observations, *arXiv preprint arXiv:1810.00042* .
- Yang, S. and Lok, J. J. (2016). A goodness-of-fit test for structural nested mean models, *Biometrika* **103**: 734–741.
- Zhao, Y.-Q., Zeng, D., Tangen, C. M. and Leblanc, M. L. (2019). Robustifying trial-derived optimal treatment rules for a target population, *Electronic Journal of Statistics* **13**: 1717–1743.